Lyrica Scheduling Decision Expected In Second Quarter; Launch To Follow
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer hopes to complete the DEA scheduling process for Lyrica during the second quarter, clearing the way for the launch of the neuropathic pain agent